Of the 108 breast cancer tumors, 81 tumors (75%) were hormone receptor positive, 20 tumors (18.5%) were HER2 positive of which 11 tumors (10.2%) were triple-positive (ER+, PR+, HER2+), and 16 cases (14.8%) had triple-negative tumors. This evidence concerns the gene NR4A1 and breast cancer.